The DOI matches its Crossref record.
Use of short‐term efficacy/toxicity tradeoffs to select second‐line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
Abstract
Objective. Preferred drugs for rheumatoid arthritis (RA) should be those that have maximal efficacy with the least toxicity. We evaluated the efficacy and toxicity tradeoffs for drugs frequently used in the treatment of RA. Methods. We updated 2 metaanalyses of published clinical trials, by adding trials published through 1990 and trials of azathioprine (AZA). We tested 3 different definitions of efficacy, each plotted against 3 different toxicity measures, for antimalarial drugs, methotrexate (MTX), auranofin, injectable gold, D‐penicillamine, sulfasalazine (SSZ), AZA, and placebo. Efficacy measures included composite efficacy (a combination of joint count, grip strength, and erythrocyte sedimentation rate), tender joint count alone, and a measure based on how many patients dropped out due to inefficacy. Toxicity measures were the proportion dropping out due to toxicity, the same dropouts with side effects weighted for severity using a modification of a published toxicity index, and the proportion with severe toxicities (defined as a score of at least 7 of 10 on the toxicity index). The latter were usually organ toxicities (e.g., cytopenias and renal involvement). Results. All 9 efficacy/toxicity tradeoff plots suggested that MTX and antimalarial drugs had the highest efficacy relative to toxicity. MTX scored among the most efficacious of the drugs and, of these, had the least toxicity. Antimalarial drugs, though showing only moderate efficacy, had the lowest toxicity rate of all the drugs. SSZ scored close to MTX but was, in general, slightly more toxic. Conclusion. In the short‐term context of clinical trials, antimalarial drugs and MTX have the best efficacy/toxicity tradeoffs and may, therefore, be the preferred drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gömör, B., Van den Bosch, F., Nordström, D., Bjørneboe, O., Dahl, R., et al. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.655 · Cited by 472
Strategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
Chen, Y.-F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., & Burls, A. (2006) · Health Technology Assessment · doi:10.3310/hta10420 · Cited by 406
Van Ede, A. E., Laan, R. F. J. M., Rood, M. J., Huizinga, T. W. J., Van De Laar, M. A. F. J., Denderen, C. J. V., Westgeest, T. A. A., Romme, T. C., De Rooij, D.-J. R. A. M., Jacobs, M. J. M., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1515::aid-art273>3.0.co;2-7 · Cited by 401
Moher, Cook, Jadad, Tugwell, Moher, Jones, Pham, & Klassen (1999) · Health Technology Assessment · doi:10.3310/hta3120 · Cited by 368
Shea, B., Swinden, M. V., Tanjong Ghogomu, E., Ortiz, Z., Katchamart, W., Rader, T., Bombardier, C., Wells, G. A., & Tugwell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000951.pub2 · Cited by 347
Methotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
Inflammatory mechanisms in Alzheimer's disease: implications for therapy
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1105 · Cited by 326
Methotrexate for treating rheumatoid arthritis
Lopez-Olivo, M. A., Siddhanamatha, H. R., Shea, B., Tugwell, P., Wells, G. A., & Suarez-Almazor, M. E. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000957.pub2 · Cited by 277
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review
Whittle, S. L. (2003) · Rheumatology · doi:10.1093/rheumatology/keh088 · Cited by 266
Leflunomide: A Review of its Use in Active Rheumatoid Arthritis
Prakash, A., & Jarvis, B. (1999) · Drugs · doi:10.2165/00003495-199958060-00010 · Cited by 135
Jobanputra, P., Barton, P., Bryan, S., & Burls, A. (2002) · Health Technology Assessment · doi:10.3310/hta6210 · Cited by 126
Metadata
- Authors
- Felson, D. T., Anderson, J. J., & Meenan, R. F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1992-10
- Volume
- 35
- Issue
- 10
- Pages
- 1117-1125
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2116467791
- Cited by
- 230
- References
- 0
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.